$NEPH
NEPHROS INC Stock $neph

$neph Overview Financials Valuation SEC Filings Company Website

2023 Q3 Form 10-Q Financial Statement

#000149315223027337 Filed on August 09, 2023

Income Statement

Concept	2023 Q3	2023 Q2	2022 Q2
Revenue	$3.742M	$3.545M	$2.884M
YoY Change	55.33%	22.92%	27.27%
Cost Of Revenue	$1.548M	$1.466M	$1.523M
YoY Change	-6.01%	-3.74%	53.68%
Gross Profit	$2.194M	$2.079M	$1.361M
YoY Change	187.93%	52.76%	6.75%
Gross Profit Margin	58.63%	58.65%	47.19%
Selling, General & Admin	$2.137M	$2.239M	$2.070M
YoY Change	22.6%	8.16%	11.65%
% of Gross Profit	97.4%	107.7%	152.09%
Research & Development	$205.0K	$221.0K	$431.0K
YoY Change	-18.65%	-48.72%	-11.5%
% of Gross Profit	9.34%	10.63%	31.67%
Depreciation & Amortization	$50.00K	$54.00K	$104.0K
YoY Change	4.17%	-48.08%	112.24%
% of Gross Profit	2.28%	2.6%	7.64%
Operating Expenses	$2.397M	$2.514M	$2.565M
YoY Change	17.33%	-1.99%	7.23%
Operating Profit	-$203.0K	-$435.0K	-$1.204M
YoY Change	-84.15%	-63.87%	7.79%
Interest Expense			$6.000K
YoY Change			-45.45%
% of Operating Profit
Other Income/Expense, Net	$21.00K	$2.000K	$67.00K
YoY Change	-32.26%	-97.01%	-844.44%
Pretax Income	-$180.0K	-$433.0K	-$1.137M
YoY Change	-85.6%	-61.92%	0.98%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$182.0K	-$433.0K	-$1.137M
YoY Change	-94.37%	-61.92%	0.98%
Net Earnings / Revenue	-4.86%	-12.21%	-39.42%
Basic Earnings Per Share	-$0.02	-$0.04	-$0.12
Diluted Earnings Per Share	-$0.02	-$0.04	-$116.8K
COMMON SHARES
Basic Shares Outstanding	10.48M shares	10.48M shares	10.30M shares
Diluted Shares Outstanding	10.46M shares	10.30M shares	10.30M shares

Balance Sheet

Concept	2023 Q3	2023 Q2	2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$4.620M	$4.060M	$4.179M
YoY Change	17.26%	-2.85%	-49.52%
Cash & Equivalents	$4.622M	$4.060M	$4.179M
Short-Term Investments
Other Short-Term Assets	$170.0K	$152.0K	$151.0K
YoY Change	-8.6%	0.66%	62.37%
Inventory	$2.268M	$2.126M	$4.664M
Prepaid Expenses
Receivables	$1.443M	$1.576M	$2.128M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$8.506M	$7.914M	$11.12M
YoY Change	-5.36%	-28.84%	-25.05%
LONG-TERM ASSETS
Property, Plant & Equipment	$88.00K	$98.00K	$450.0K
YoY Change	-83.46%	-78.22%	-62.5%
Goodwill	$800.0K	$800.0K	$800.0K
YoY Change	0.0%	0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$123.0K	$54.00K	$67.00K
YoY Change	112.07%	-19.4%	-35.58%
Total Long-Term Assets	$2.413M	$2.472M	$3.831M
YoY Change	8.84%	-35.47%	21.58%
TOTAL ASSETS
Total Short-Term Assets	$8.506M	$7.914M	$11.12M
Total Long-Term Assets	$2.413M	$2.472M	$3.831M
Total Assets	$10.92M	$10.39M	$14.95M
YoY Change	-2.55%	-30.54%	-16.89%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$805.0K	$302.0K	$1.411M
YoY Change	3.34%	-78.6%	28.27%
Accrued Expenses	$712.0K	$572.0K	$185.0K
YoY Change	42.12%	209.19%	-77.44%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$10.00K	$8.000K	$220.0K
YoY Change	-92.91%	-96.36%	-12.0%
Total Short-Term Liabilities	$1.828M	$1.197M	$2.111M
YoY Change	28.64%	-43.3%	-2.72%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$11.00K
YoY Change	-100.0%	-100.0%	-95.69%
Other Long-Term Liabilities	$470.0K	$534.0K	$350.0K
YoY Change	133.83%	52.57%	-39.13%
Total Long-Term Liabilities	$470.0K	$534.0K	$361.0K
YoY Change	131.53%	47.92%	-56.51%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.828M	$1.197M	$2.111M
Total Long-Term Liabilities	$470.0K	$534.0K	$361.0K
Total Liabilities	$2.297M	$1.731M	$2.472M
YoY Change	-53.15%	-29.98%	-59.17%
SHAREHOLDERS EQUITY
Retained Earnings	-$143.8M	-$143.6M	-$138.8M
YoY Change	1.27%	3.46%
Common Stock	$10.00K	$10.00K	$10.00K
YoY Change	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$8.622M	$8.655M	$9.221M
YoY Change
Total Liabilities & Shareholders Equity	$10.92M	$10.39M	$14.95M
YoY Change	-2.55%	-30.54%	-16.89%

Cashflow Statement

Concept	2023 Q3	2023 Q2	2022 Q2
OPERATING ACTIVITIES
Net Income	-$182.0K	-$433.0K	-$1.137M
YoY Change	-94.37%	-61.92%	0.98%
Depreciation, Depletion And Amortization	$50.00K	$54.00K	$104.0K
YoY Change	4.17%	-48.08%	112.24%
Cash From Operating Activities	$570.0K	$226.0K	-$1.072M
YoY Change	-435.29%	-121.08%	857.14%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00	-$103.0K
YoY Change		-100.0%	3333.33%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	$0.00	$0.00	-$103.0K
YoY Change		-100.0%	3333.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	-2.000K	-67.00K
YoY Change	-100.0%	-97.01%	-129.39%
NET CHANGE
Cash From Operating Activities	570.0K	226.0K	-1.072M
Cash From Investing Activities	0.000	0.000	-103.0K
Cash From Financing Activities	0.000	-2.000K	-67.00K
Net Change In Cash	570.0K	224.0K	-1.242M
YoY Change	-338.49%	-118.04%	-1199.12%
FREE CASH FLOW
Cash From Operating Activities	$570.0K	$226.0K	-$1.072M
Capital Expenditures	$0.00	$0.00	-$103.0K
Free Cash Flow	$570.0K	$226.0K	-$969.0K
YoY Change	-435.29%	-123.32%	788.99%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q2	us-gaap	Minority Interest MinorityInterest		usd
	dei	Entity Central Index Key EntityCentralIndexKey	0001196298
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q2	us-gaap	Secured Debt Current SecuredDebtCurrent		usd
CY2023Q2	NEPH	Equipment Financing Debt Non Current EquipmentFinancingDebtNonCurrent		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q2	us-gaap	Interest Expense InterestExpense		usd
CY2023Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax		usd
	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax		usd
CY2023Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest		usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest		usd
CY2023Q2	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare
CY2023Q2	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Diluted Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare
	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare
	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Diluted Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare
CY2023Q2	NEPH	Income Loss From Continuing Operations Attributable To Noncontrolling Interest Per Basic Share IncomeLossFromContinuingOperationsAttributableToNoncontrollingInterestPerBasicShare
CY2023Q2	NEPH	Income Loss From Continuing Operations Attributable To Noncontrolling Interest Per Diluted Share IncomeLossFromContinuingOperationsAttributableToNoncontrollingInterestPerDilutedShare
	NEPH	Income Loss From Continuing Operations Attributable To Noncontrolling Interest Per Basic Share IncomeLossFromContinuingOperationsAttributableToNoncontrollingInterestPerBasicShare
	NEPH	Income Loss From Continuing Operations Attributable To Noncontrolling Interest Per Diluted Share IncomeLossFromContinuingOperationsAttributableToNoncontrollingInterestPerDilutedShare
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax		usd
CY2023Q2	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest		usd
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest		usd
CY2023Q1	us-gaap	Noncontrolling Interest Increase From Subsidiary Equity Issuance NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance		usd
CY2022Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures		usd
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized		usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders		usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations		usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability		usd
CY2022Q2	NEPH	Disposal Group Including Discontinued Operation Impairment Of Assets Held For Sale DisposalGroupIncludingDiscontinuedOperationImpairmentOfAssetsHeldForSale		usd
	NEPH	Disposal Group Including Discontinued Operation Impairment Of Assets Held For Sale DisposalGroupIncludingDiscontinuedOperationImpairmentOfAssetsHeldForSale		usd
CY2023Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess		usd
CY2023Q2	us-gaap	Indefinite Lived License Agreements IndefiniteLivedLicenseAgreements	335000	usd
CY2023Q2	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent		usd
CY2023Q2	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo		usd
CY2023Q2	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree		usd
CY2023Q2	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour		usd
CY2023Q2	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-32288
	dei	Entity Registrant Name EntityRegistrantName	NEPHROS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	13-3971809
	dei	Entity Address Address Line1 EntityAddressAddressLine1	380 Lackawanna Place
	dei	Entity Address City Or Town EntityAddressCityOrTown	South Orange
	dei	Entity Address State Or Province EntityAddressStateOrProvince	NJ
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	07079
	dei	City Area Code CityAreaCode	(201)
	dei	Local Phone Number LocalPhoneNumber	343-5202
	dei	Security12b Title Security12bTitle	Common stock, par value $0.001 per share
	dei	Trading Symbol TradingSymbol	NEPH
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	10484932	shares
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4060000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3634000	usd
CY2023Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1576000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1286000	usd
CY2023Q2	us-gaap	Inventory Net InventoryNet	2126000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	3153000	usd
CY2023Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	152000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	188000	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	7914000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	8261000	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	98000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	116000	usd
CY2023Q2	NEPH	Operating And Finance Lease Right Of Use Assets OperatingAndFinanceLeaseRightOfUseAssets	824000	usd
CY2022Q4	NEPH	Operating And Finance Lease Right Of Use Assets OperatingAndFinanceLeaseRightOfUseAssets	984000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	402000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	423000	usd
CY2023Q2	us-gaap	Goodwill Goodwill	759000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	759000	usd
CY2023Q2	us-gaap	Indefinite Lived License Agreements IndefiniteLivedLicenseAgreements	335000	usd
CY2022Q4	us-gaap	Indefinite Lived License Agreements IndefiniteLivedLicenseAgreements	402000	usd
CY2023Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	54000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	54000	usd
CY2023Q2	us-gaap	Assets Assets	10386000	usd
CY2022Q4	us-gaap	Assets Assets	10999000	usd
CY2022Q4	us-gaap	Secured Debt Current SecuredDebtCurrent	71000	usd
CY2023Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	302000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	740000	usd
CY2023Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	572000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	285000	usd
CY2023Q2	NEPH	Operating And Finance Lease Liabilities Current OperatingAndFinanceLeaseLiabilitiesCurrent	323000	usd
CY2022Q4	NEPH	Operating And Finance Lease Liabilities Current OperatingAndFinanceLeaseLiabilitiesCurrent	316000	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	1197000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1412000	usd
CY2022Q4	NEPH	Equipment Financing Debt Non Current EquipmentFinancingDebtNonCurrent	1000	usd
CY2023Q2	NEPH	Operating And Finance Lease Liabilities Non Current OperatingAndFinanceLeaseLiabilitiesNonCurrent	534000	usd
CY2022Q4	NEPH	Operating And Finance Lease Liabilities Non Current OperatingAndFinanceLeaseLiabilitiesNonCurrent	705000	usd
CY2023Q2	us-gaap	Liabilities Liabilities	1731000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	2118000	usd
CY2023Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2023Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	40000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	40000000	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	10484932	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	10484932	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	10297429	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	10297429	shares
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	10000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	10000	usd
CY2023Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	152215000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	148413000	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-143570000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-142831000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	8655000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	5592000	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	3289000	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	8655000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	8881000	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	10386000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	10999000	usd
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3545000	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2850000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7242000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	5009000	usd
CY2023Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1466000	usd
CY2022Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1455000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	3052000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2561000	usd
CY2023Q2	us-gaap	Gross Profit GrossProfit	2079000	usd
CY2022Q2	us-gaap	Gross Profit GrossProfit	1395000	usd
	us-gaap	Gross Profit GrossProfit	4190000	usd
	us-gaap	Gross Profit GrossProfit	2448000	usd
CY2023Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2239000	usd
CY2022Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1885000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4363000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4062000	usd
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	221000	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	273000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	460000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	645000	usd
CY2023Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	54000	usd
CY2022Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	51000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	108000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	102000	usd
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	2514000	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	2209000	usd
	us-gaap	Operating Expenses OperatingExpenses	4931000	usd
	us-gaap	Operating Expenses OperatingExpenses	4809000	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-435000	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-814000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-741000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-2361000	usd
CY2022Q2	us-gaap	Interest Expense InterestExpense	6000	usd
	us-gaap	Interest Expense InterestExpense	1000	usd
	us-gaap	Interest Expense InterestExpense	13000	usd
CY2023Q2	us-gaap	Interest Income Other InterestIncomeOther	13000	usd
CY2022Q2	us-gaap	Interest Income Other InterestIncomeOther	1000	usd
	us-gaap	Interest Income Other InterestIncomeOther	25000	usd
	us-gaap	Interest Income Other InterestIncomeOther	3000	usd
CY2023Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-11000	usd
CY2022Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	72000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-22000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	63000	usd
CY2023Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2000	usd
CY2022Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	67000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	53000	usd
CY2023Q2	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-433000	usd
CY2022Q2	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-747000	usd
	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-739000	usd
	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-2308000	usd
CY2022Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-390000	usd
	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-796000	usd
CY2023Q2	us-gaap	Profit Loss ProfitLoss	-433000	usd
CY2022Q2	us-gaap	Profit Loss ProfitLoss	-1137000	usd
	us-gaap	Profit Loss ProfitLoss	-739000	usd
	us-gaap	Profit Loss ProfitLoss	-3104000	usd
CY2022Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	66000	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	129000	usd
CY2023Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-433000	usd
CY2022Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1203000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-739000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3233000	usd
CY2023Q2	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.04
CY2023Q2	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.04
CY2022Q2	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.07
CY2022Q2	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.07
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.07
	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.07
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.22
	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.22
CY2022Q2	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare	-0.04
CY2022Q2	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Diluted Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare	-0.04
	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare	-0.08
	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Diluted Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare	-0.08
CY2023Q2	NEPH	Income Loss From Continuing And Discontinued Operation Net Of Tax Per Basic Share IncomeLossFromContinuingAndDiscontinuedOperationNetOfTaxPerBasicShare	-0.04
CY2023Q2	NEPH	Income Loss From Continuing And Discontinued Operation Net Of Tax Per Diluted Share IncomeLossFromContinuingAndDiscontinuedOperationNetOfTaxPerDilutedShare	-0.04
CY2022Q2	NEPH	Income Loss From Continuing And Discontinued Operation Net Of Tax Per Basic Share IncomeLossFromContinuingAndDiscontinuedOperationNetOfTaxPerBasicShare	-0.11
CY2022Q2	NEPH	Income Loss From Continuing And Discontinued Operation Net Of Tax Per Diluted Share IncomeLossFromContinuingAndDiscontinuedOperationNetOfTaxPerDilutedShare	-0.11
	NEPH	Income Loss From Continuing And Discontinued Operation Net Of Tax Per Basic Share IncomeLossFromContinuingAndDiscontinuedOperationNetOfTaxPerBasicShare	-0.07
	NEPH	Income Loss From Continuing And Discontinued Operation Net Of Tax Per Diluted Share IncomeLossFromContinuingAndDiscontinuedOperationNetOfTaxPerDilutedShare	-0.07
	NEPH	Income Loss From Continuing And Discontinued Operation Net Of Tax Per Basic Share IncomeLossFromContinuingAndDiscontinuedOperationNetOfTaxPerBasicShare	-0.30
	NEPH	Income Loss From Continuing And Discontinued Operation Net Of Tax Per Diluted Share IncomeLossFromContinuingAndDiscontinuedOperationNetOfTaxPerDilutedShare	-0.30
CY2022Q2	NEPH	Income Loss From Continuing Operations Attributable To Noncontrolling Interest Per Basic Share IncomeLossFromContinuingOperationsAttributableToNoncontrollingInterestPerBasicShare	-0.01
CY2022Q2	NEPH	Income Loss From Continuing Operations Attributable To Noncontrolling Interest Per Diluted Share IncomeLossFromContinuingOperationsAttributableToNoncontrollingInterestPerDilutedShare	-0.01
	NEPH	Income Loss From Continuing Operations Attributable To Noncontrolling Interest Per Basic Share IncomeLossFromContinuingOperationsAttributableToNoncontrollingInterestPerBasicShare	-0.01
	NEPH	Income Loss From Continuing Operations Attributable To Noncontrolling Interest Per Diluted Share IncomeLossFromContinuingOperationsAttributableToNoncontrollingInterestPerDilutedShare	-0.01
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.04
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.04
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.12
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.12
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.07
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.07
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.31
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.31
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	10297429	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	10297429	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	10299148	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	10299148	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	10297429	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	10297429	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	10265267	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	10265267	shares
CY2023Q2	us-gaap	Profit Loss ProfitLoss	-433000	usd
CY2022Q2	us-gaap	Profit Loss ProfitLoss	-1137000	usd
	us-gaap	Profit Loss ProfitLoss	-739000	usd
	us-gaap	Profit Loss ProfitLoss	-3104000	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-3000	usd
CY2023Q2	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-433000	usd
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-1137000	usd
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-739000	usd
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-3107000	usd
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	66000	usd
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	129000	usd
CY2023Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-433000	usd
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1203000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-739000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3236000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	8881000	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-306000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	319000	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	8894000	usd
CY2023Q2	us-gaap	Profit Loss ProfitLoss	-433000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	194000	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	8655000	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	14749000	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-1967000	usd
CY2022Q1	us-gaap	Noncontrolling Interest Increase From Subsidiary Equity Issuance NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance	188000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-3000	usd
CY2022Q1	NEPH	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	163000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	272000	usd
CY2022Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	13402000	usd
CY2022Q2	us-gaap	Profit Loss ProfitLoss	-1137000	usd
CY2022Q2	NEPH	Elimination Of Cumulative Translation Adjustment Upon Closing Of Wholly Owned Foreign Subsidiary EliminationOfCumulativeTranslationAdjustmentUponClosingOfWhollyOwnedForeignSubsidiary	-61000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	277000	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	12481000	usd
	us-gaap	Profit Loss ProfitLoss	-739000	usd
	us-gaap	Profit Loss ProfitLoss	-3104000	usd
	us-gaap	Depreciation Depreciation	19000	usd
	us-gaap	Depreciation Depreciation	53000	usd
	us-gaap	Amortization Of Deferred Charges AmortizationOfDeferredCharges	88000	usd
	us-gaap	Amortization Of Deferred Charges AmortizationOfDeferredCharges	143000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	513000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	549000	usd
	us-gaap	Inventory Write Down InventoryWriteDown	106000	usd
	us-gaap	Inventory Write Down InventoryWriteDown	108000	usd
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	60000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	290000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	487000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-920000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-23000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-35000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-74000	usd
	NEPH	Increase Decrease In Right Of Use Assets IncreaseDecreaseInRightOfUseAssets	-160000	usd
	NEPH	Increase Decrease In Right Of Use Assets IncreaseDecreaseInRightOfUseAssets	-174000	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-2000	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-22000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-437000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	77000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	285000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-262000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-160000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-179000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	502000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2869000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	137000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-137000	usd
	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	188000	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	4000	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	3000	usd
	NEPH	Principal Payments On Equipment Financing PrincipalPaymentsOnEquipmentFinancing	1000	usd
	NEPH	Principal Payments On Equipment Financing PrincipalPaymentsOnEquipmentFinancing	1000	usd
	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	71000	usd
	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	133000	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	163000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-76000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	214000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-2000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	426000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2794000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	3634000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	6973000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	4060000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	4179000	usd
	us-gaap	Interest Paid Net InterestPaidNet	2000	usd
	us-gaap	Interest Paid Net InterestPaidNet	13000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	69000	usd
	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_806_eus-gaap--NatureOfOperations_zcsvzp33kocj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>Note 1 – <span id="xdx_827_zEaZNbASY0D5">Organization and Nature of Operations</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Nephros, Inc. (“Nephros” or the “Company”) was incorporated under the laws of the State of Delaware on April 3, 1997. The Company was founded by health professionals, scientists and engineers affiliated with Columbia University to develop advanced end stage renal disease (“ESRD”) therapy technology and products.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Beginning in 2009, Nephros introduced high performance liquid purification filters to meet the demand for water purification in certain medical markets. The Company’s filters, generally classified as ultrafilters, are primarily used in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, and in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate. The Company also develops and sells water filtration products for commercial applications, focusing on the hospitality and food service markets. The water filtration business is a reportable segment, referred to as the Water Filtration segment.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">On October 4, 2022, the Company entered into a definitive asset purchase agreement with a third party for the sale of substantially all of the Company’s Pathogen Detection Systems (“PDS”) business, which had been previously reported as a separate reportable operating segment. As a result of the sale of the PDS business, we completely exited the PDS business. As a result, we determined that our PDS business had met the criteria for discontinued operations as of September 30, 2022. We no longer separately report the PDS business as a separate reportable segment in our financial statements including in this Quarterly Report for any of the periods presented.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">In July 2018, the Company formed a subsidiary, Specialty Renal Products, Inc. (“SRP”), to drive the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. After SRP’s formation, the Company assigned to SRP all of the Company’s rights to three patents relating to the Company’s hemodiafiltration technology, which were carried at zero book value. On March 9, 2023, the SRP Stockholders approved a plan of dissolution to wind down SRP’s operations, liquidate SRP’s remaining assets and dissolve SRP. Pursuant to such plan, SRP filed a certificate of dissolution with the State of Delaware on April 13, 2023. As a result of the SRP Stockholders’ approval of the plan of dissolution and provisions therein and the extent of SRP’s liabilities, there are no assets available for distribution to the holders of any of SRP’s capital stock, including its Series A Preferred Stock. As such, the value of the SRP Series A Preferred Stock was written to zero and the impact recorded to the Company’s additional paid in capital as the Company retained control of SRP.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The Company’s primary U.S. facilities are located at 380 Lackawanna Place, South Orange, New Jersey 07079 and 3221 Polaris Avenue, Las Vegas, Nevada 89102. These locations house the Company’s corporate headquarters, research, manufacturing, and distribution facilities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p>
CY2023Q2	us-gaap	Cost Of Goods And Services Sold Depreciation CostOfGoodsAndServicesSoldDepreciation	1000	usd
	us-gaap	Cost Of Goods And Services Sold Depreciation CostOfGoodsAndServicesSoldDepreciation	2000	usd
CY2022Q2	us-gaap	Cost Of Goods And Services Sold Depreciation CostOfGoodsAndServicesSoldDepreciation	12000	usd
	us-gaap	Cost Of Goods And Services Sold Depreciation CostOfGoodsAndServicesSoldDepreciation	16000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_844_eus-gaap--UseOfEstimates_zzFPy9Gm07d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b><span id="xdx_86C_z2KxkJG0ii57">Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 34.1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities, at the date of the financial statements, and the reported amount of revenues and expenses, during the reporting period. Actual results could differ materially from those estimates. Included in these estimates are assumptions about the collection of accounts receivable, value of inventories, useful life of fixed assets and intangible assets, the assessment of expected cash flows used in evaluating goodwill and other long-lived assets, and assumptions used in determining stock compensation such as expected volatility and risk-free interest rate.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b> </b></span></p>
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-143600000	usd
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_847_eus-gaap--ConcentrationRiskCreditRisk_zU4zfzLH0fk1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b><span id="xdx_862_zA8gwVNduFnc">Concentration of Credit Risk</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The Company deposits its cash in financial institutions. At times, such deposits may be in excess of insured limits. To date, the Company has not experienced any impairment losses on its cash. The Company also limits its credit risk with respect to accounts receivable by performing credit evaluations when deemed necessary.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b> </b></span></p>
CY2023Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	usd
CY2022Q2	us-gaap	Disposal Group Including Discontinued Operation Revenue DisposalGroupIncludingDiscontinuedOperationRevenue	34000	usd
CY2022Q2	us-gaap	Disposal Group Including Discontinued Operation Gross Profit Loss DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss	-34000	usd
CY2022Q2	NEPH	Disposal Group Including Discontinued Operation Research And Development Expenses DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpenses	158000	usd
CY2022Q2	us-gaap	Disposal Group Including Discontinued Operation Depreciation And Amortization DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization	13000	usd
CY2022Q2	us-gaap	Disposal Group Including Discontinued Operation General And Administrative Expense DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense	185000	usd
CY2022Q2	us-gaap	Disposal Group Including Discontinued Operation Operating Expense DisposalGroupIncludingDiscontinuedOperationOperatingExpense	356000	usd
CY2022Q2	us-gaap	Disposal Group Including Discontinued Operation Operating Income Loss DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss	-390000	usd
CY2022Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-390000	usd
	us-gaap	Disposal Group Including Discontinued Operation Revenue DisposalGroupIncludingDiscontinuedOperationRevenue	62000	usd
	us-gaap	Disposal Group Including Discontinued Operation Gross Profit Loss DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss	-62000	usd
	NEPH	Disposal Group Including Discontinued Operation Research And Development Expenses DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpenses	364000	usd
	us-gaap	Disposal Group Including Discontinued Operation Depreciation And Amortization DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization	14000	usd
	us-gaap	Disposal Group Including Discontinued Operation General And Administrative Expense DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense	356000	usd
	us-gaap	Disposal Group Including Discontinued Operation Operating Expense DisposalGroupIncludingDiscontinuedOperationOperatingExpense	734000	usd
	us-gaap	Disposal Group Including Discontinued Operation Operating Income Loss DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss	-796000	usd
	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-796000	usd
CY2023Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1674000	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	2709000	usd
CY2023Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	452000	usd
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	422000	usd
CY2022Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	22000	usd
CY2023Q2	us-gaap	Inventory Net InventoryNet	2126000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	3153000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	590000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-188000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	402000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	590000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-167000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	423000	usd
CY2023Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	11000	usd
CY2022Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	11000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	21000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	32000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	32000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	32000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	32000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	32000	usd
CY2023Q2	us-gaap	Goodwill Goodwill	800000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	800000	usd
CY2023Q2	us-gaap	Finite Lived License Agreements Gross FiniteLivedLicenseAgreementsGross	2300000	usd
CY2022Q4	us-gaap	Indefinite Lived License Agreements IndefiniteLivedLicenseAgreements	400000	usd
CY2023Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	90000	usd
CY2022Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	102000	usd
CY2023Q2	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	2000	usd
CY2022Q2	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	1000	usd
CY2023Q2	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	1000	usd
CY2022Q2	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	1000	usd
CY2023Q2	NEPH	Finance Lease Cost FinanceLeaseCost	3000	usd
CY2022Q2	NEPH	Finance Lease Cost FinanceLeaseCost	2000	usd
CY2023Q2	us-gaap	Variable Lease Cost VariableLeaseCost	3000	usd
CY2022Q2	us-gaap	Variable Lease Cost VariableLeaseCost	10000	usd
CY2023Q2	us-gaap	Lease Cost LeaseCost	96000	usd
CY2022Q2	us-gaap	Lease Cost LeaseCost	114000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	182000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	213000	usd
	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	4000	usd
	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	5000	usd
	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	2000	usd
	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	3000	usd
	NEPH	Finance Lease Cost FinanceLeaseCost	6000	usd
	NEPH	Finance Lease Cost FinanceLeaseCost	8000	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	7000	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	19000	usd
	us-gaap	Lease Cost LeaseCost	195000	usd
	us-gaap	Lease Cost LeaseCost	240000	usd
	us-gaap	Operating Lease Lease Income Lease Payments OperatingLeaseLeaseIncomeLeasePayments	160000	usd
	us-gaap	Operating Lease Lease Income Lease Payments OperatingLeaseLeaseIncomeLeasePayments	211000	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	4000	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	3000	usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	816000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	972000	usd
CY2023Q2	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	8000	usd
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	12000	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	315000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	308000	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	534000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	700000	usd
CY2023Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	849000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1008000	usd
CY2023Q2	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	8000	usd
CY2022Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	8000	usd
CY2022Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	5000	usd
CY2023Q2	us-gaap	Finance Lease Liability FinanceLeaseLiability	8000	usd
CY2022Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	13000	usd
CY2023Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y7M6D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y10M24D
CY2023Q2	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P1Y1M6D
CY2022Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P1Y6M14D
CY2023Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.080	pure
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.080	pure
CY2023Q2	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.080	pure
CY2022Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.080	pure
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	105000	usd
CY2023Q2	us-gaap	Finance Lease Liability Payments Remainder Of Fiscal Year FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear	4000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	299000	usd
CY2023Q2	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	4000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	163000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	168000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	158000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	893000	usd
CY2023Q2	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	8000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	44000	usd
CY2023Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	849000	usd
CY2023Q2	us-gaap	Finance Lease Liability FinanceLeaseLiability	8000	usd
CY2023Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	1000000.0	usd
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y6M

Files In Submission

Name	View Source	Status
0001493152-23-027337-index-headers.html	Edgar Link	pending
0001493152-23-027337-index.html	Edgar Link	pending
0001493152-23-027337.txt	Edgar Link	pending
0001493152-23-027337-xbrl.zip	Edgar Link	pending
ex10-1.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
neph-20230630.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
neph-20230630_lab.xml	Edgar Link	unprocessable
neph-20230630_def.xml	Edgar Link	unprocessable
neph-20230630_pre.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
neph-20230630_cal.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NEPH
NEPHROS INC Stock $neph

2023 Q3 Form 10-Q Financial Statement

#000149315223027337 Filed on August 09, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NEPH NEPHROS INC Stock $neph

2023 Q3 Form 10-Q Financial Statement

#000149315223027337 Filed on August 09, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NEPH
NEPHROS INC Stock $neph